US Patent Issued to Health Research on July 7 for "Exploiting estrogen receptor beta and TP53 interaction as a new therapeutic strategy for cancer" (New York Inventor)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,032, issued on July 7, was assigned to Health Research Inc. (Buffalo, N.Y.).

"Exploiting estrogen receptor beta and TP53 interaction as a new therapeutic strategy for cancer" was invented by Gokul M. Das (Buffalo, N.Y.).

According to the abstract* released by the U.S. Patent & Trademark Office: "To induce cancer cell death, cancer cells are selected that express estrogen-receptor Beta (ERBeta) and mutant tumor protein 53 (TP53). An agent that increases ERBeta protein expression is administered to the cells to induce cell death. To treat a subject having a cancer that is characterized by cancer cells expressing ERBeta and mutant TP53, an agent that increases ERBeta protein expressi...